Inhibition of intra-tumoral angiogenesis and glioma growth by the fibroblast growth factor inhibitor 1,3,6-naphthalenetrisulfonate

Neurological Research

Volumn 21, Issue 5, 1999, Pages 481-487

  Cuevas, Pedro ^a   Carceller, Fernando ^a   Reimers, Diana ^a   Cuevas, Begoña ^a   Lozano, Rosa M ^b   Gimenez Gallego G ^b  

^a HOSPITAL RAMÓN Y CAJAL   (Spain)

^b CSIC   (Spain)

Author keywords

Antiangiogenesis therapy; Fibroblast growth factor; Glioma; Naphthalenetrisulfonate; Rabbit cornea

Indexed keywords

1,3,6 NAPHTHALENETRISULFONATE; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; FIBROBLAST GROWTH FACTOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CONTROLLED STUDY; DRUG MECHANISM; EXPERIMENTAL NEOPLASM; GLIOMA; HISTOPATHOLOGY; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; RABBIT; TOPICAL DRUG ADMINISTRATION;

EID: 0032778003     PISSN: 01616412     EISSN: None     Source Type: Journal    
DOI: 10.1080/01616412.1999.11740962     Document Type: Article

References (46)

1. Folkman J. Tumor angiogenesis: Therapeutic implications. N Engl J Med 1971; 285: 1182-1186
2. Folkman J. Angiogenesis in cancer, vascular rheumatoid and other disease. Nature Med 1995; 1: 27-31
3. Denekamp J. Review Article: Angiogenesis, neovascular proliferation and vascular pathophysiology as targets for cancer therapy. Br J Radiol 1993; 66: 181-196
4. Gross JL, Herblin WF, Dusak BA. Effects of modulation of basic fibroblast growth factor on tumor growth in vivo. J Natl Cancer Inst 1993; 85: 121-131
5. Mattern J, Koomagi R, Volm N. Coexpression of VEGF and bFCF In human epidermoid lung cancer is associated with increased vessel density. Anticancer Res 1997; 17: 2249-2252
6. Stan AC, Nemati MN, Pietsch T, et al. In vivo inhibition of angiogenesis and growth of the human U-87 malignant glial tumor by treatment with an antibody against basic fibroblast growth factor. J Neurosurg 1995; 82: 1044-1052
7. Takahashi JA, Fukumoto M, Kozai Y, et al. Inhibition of cell growth and tumorigenesis of human glioblastoma cells by a neutralizing antibody against human basic fibroblast growth factor. FEBS Lett 1991; 288: 65-71
8. Wang Y, Becker D. Antisense targeting of basic fibroblast growth factor receptor-1 in human melanomas blocks intratumoral angiogenesis and tumor growth. Nature Med 1997; 8: 887-893
9. Mandriota SJ, Pepper MS. Vascular endothelial growth factor-induced in vitro angiogenesis and plasminogen activator expression are dependent on endogenous basic fibroblast growth factor. J Cell Sci 1997; 110: 2294-2302
10. Eisenberger MA, Fontana JA. Suramin, an active nonhormonal cytotoxic drug for treatment of prostate cancer. Compelling reasons for testing in patients with hormone-refractory breast cancer. J Natl Cancer Inst 1992; 84: 3-5
11. Wellstein A, Zugmaier G, Califano JA, et al. Tumor growth dependent on Kaposi's sarcoma-derived fibroblast growth factor inhibited by pentosan polysulfate. J Natl Cancer Inst 1991; 83: 716-720
12. Lozano RM, Jiménez MA, Santoro J, et al. Solution structure of acidic fibroblast growth factor bound to 1,3,6-naphthalenetrisulfonate. A minimal model for the anti-tumoral action of suramins and sudaristas. J Mol Biol 1998; 281: 899-915
13. Cuevas P, Lozano RM, Giménez-Gallego G. Suppression of acidic fibroblast growth factor-dependent angiogenesis by the antigrowth activity of 1,3,6-naphthalenetrisulfonate. Neurol Res 1999; 21: 191 -194
14. Pedersen PH, New GO, Engebreaten O, et al. Heterogenous response to the growth factors (EGF, PDGF (bb), TGF-α, bFGF, IL-2) on glioma spheroid growth, migration and invasion. Int J Cancer 1994; 56: 255-261
15. Takahashi JA, Mori H, Fukumoto M, et al. Gene expression of fibroblast growth factors in human gliomas and meningiomas: Demonstration of cellular source of basic fibroblast growth factor mRNA and peptide in tumor tissues. Proc Natl Acad Sci USA 1990; 87: 5710-5714
16. Takahashi JA, Fukumoto M, Igarshi K, et al. Correlation of basic fibroblast growth factor expression levels with the degree of malignancy and vascularity in human gliomas. J Neurosurg 1992; 76: 792-798
17. Gimbrone MA, Cotran RS, Leapman SB, Folkman J. Tumor growth and neovascularization: An experimental model using the rabbit cornea. J Natl Cancer Inst 1974; 52: 413-427
18. Kaye AH, Morstyn G, Gardner Y, Pyke K. Development of a xenograft glioma model in mouse brain. Cancer Res 1986; 46: 1367-1373
19. Voest EE, Kenyon BM, O'Reilly MS, et al. Inhibition of angiogenesis in vivo by interleukin 12. J Natl Cancer Inst 1995; 87: 581-586
20. Murube J, ed. Dacriología Básica, Islasd Canarias: Universidad de La Laguna, 1981: pp. 406-421
21. Gavrieli Y, Sherman Y, Ven-Sasson SA. Identification of programmed cell death in situ via specific labelling of nuclear DNA fragmentation. J Cell Biol 1992; 119: 493-501
22. Yuan F, Chen Y, Dellian M, et al. Time-dependent vascular regression and permeability changes in established human tumor xenografts induced by an anti-vascular endothelial growth factor/ vascular permeability factor antibody. Proc Natl Acad Sci USA 1996; 93: 14765-14770
23. Jain RK, Safabakhsh N, Sckell A, et al. Endothelial cell death angiogenesis, and microvascular function after castration in an androgen-dependent tumor: Role of vascular endothelial growth factor. Proc Natl Acad Sci USA 1998; 95: 10820-10825
24. Bursch W, Oberhammer F, Jirtle RL, et al. Transforming growth factor-β1 as a signal for induction of cell death by apoptosis. Br J Cancer 1993; 67: 531-536
25. Meininger CJ. Mast cells and tumor-associated angiogenesis. Chem Immunol 1995; 62: 239-257
26. Gruber BL, Marchese MJ, Kew R. Angiogenic factors stimulate mast cell migration. Blood 1995; 86: 2499-2493
27. Collins MK, Perkins GR, Rodriguez-Tarduchy G, et al. Growth factors as survival factors: Regulation of apoptosis. Bioassay 1994; 16: 133-138
28. Araki S, Shimada Y, Kaji K, Hayashi H. Apoptosis of vascular endothelial cells by fibroblast growth factor deprivation. Biochem Biophys Res Commun 1990; 168: 1194-1200
29. Pepper MS. Transforming growth factor-beta: Vasculogenesis, angiogenesis and vessel wall integrity. Cytokine Growth Factor Res 1997; 8: 21-43
30. Wright JA, Huang A. Growth factors in mechanisms of malignancy: Roles of TGF-beta and FGF. Histol Histopathol 1996; 11: 521-536
31. Mattern J, Koomagi R, Volin N. Coexpression of VEGF and bFGF In human epidermoid lung cancer is associated with increased vessel density. Anticancer Res 1997; 17: 2249-2252
32. Seghezzi G, Patel S, Ren CJ, et al. Fibroblast growth factor-2 (FGF-2) induces vascular endothelial growth factor (VEGF) expression in the endothelial cells of forming capillaries: An autocrine mechanism contributing to angiogenesis. J Cell Biol 1998; 141: 1659-1673
33. Holmgren L, O'Reilly MS, Folkman J. Dormancy of micrometastases: Balanced proliferation and apoptosis in the presence of angiogenesis suppression. Nature Med 1995; 1: 149-153
34. Larocca RV, Stein CA, Danesi R, Myers CE. Suramin, a novel antitumor compound. J Steroid Biochem Molec Biol 1990; 37: 893-898
35. Klijn JGM, Setyono-Han B, Bakker GH, et al. Growth factor-receptor pathway interfering treatment by somastotatin analogs and suramin: Preclinical and clinical studies. J Steroid Biochem Molec Biol 1990; 37: 1089-1096
36. Meeson A, Palmer M, Calfon M, Lang R. A relationship between apoptosis and flow during programmed capillary regression is revealed by vital analysis. Development 1996; 122: 3929-3938
37. 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. Cell 1994; 79: 1157-1164
38. Kanda S, Tomasini-Johansson B, Klint P, Dixelins J, Rubin K, Claesson-Welsh L. Signaling via fibroblast growth factor receptor-1 is dependent on extracellular matrix in capillary endothelial cell differentiation. Exp Cell Res 1999; 248: 203-213
39. Cuevas P, Carceller F, Ortega S, et al. Hypotensive activity of fibroblast growth factor. Science 1991; 254: 1208-1210
40. Regli L, Anderson RE, Meyer FB. Basic fibroblast growth factor increases cortical blood flow in vivo. Brain Res 1994; 665: 155-157
41. Zhou M. Fibroblast growth factor 2 control of vascular tone. Nature Med 1998; 4: 201-207
42. Wyllie AH. Apoptosis. Br J Cancer 1993; 67: 205-208
43. Reed JC, Bcl-2: Prevention of apoptosis as a mechanism of drug resistance. Hematol Oncol Clin North Am 1995; 9: 451-474
44. Stefanik DF, Rizkalla LR, Soi A, et al. Acidic and basic fibroblast growth factors are present in glioblastoma multiforme. Cancer Res 1991; 51: 5760-5765
45. Cuevas P, Carceller F, Reimers D, et al. Acidic fibroblast growth factor rescues gerbil hippocampal neurons from ischemic apoptotic death. Neurol Res 1998; 20: 271-274
46. Melder RJ, Koening GC, Witner BP, et al. During angiogenesis, vascular endothelial growth factor and basic fibroblast growth factor regulate natural killer cell adhesion to tumor endothelium. Nature Med 1996; 2: 992-997